S
0.421
0.02 (3.85%)
| Penutupan Terdahulu | 0.406 |
| Buka | 0.426 |
| Jumlah Dagangan | 130,739 |
| Purata Dagangan (3B) | 141,700 |
| Modal Pasaran | 2,635,739 |
| Harga / Buku (P/B) | 3.60 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.30 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 165.48% |
| Nisbah Semasa (MRQ) | 1.44 |
| Aliran Tunai Operasi (OCF TTM) | -7.33 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.18 M |
| Pulangan Atas Aset (ROA TTM) | -113.74% |
| Pulangan Atas Ekuiti (ROE TTM) | -383.84% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Shuttle Pharmaceuticals Holding | - | - |
AISkor Stockmoo
-0.5
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.50 |
|
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| % Dimiliki oleh Orang Dalam | 27.06% |
| % Dimiliki oleh Institusi | 6.14% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Mar 2025 | Pengumuman | Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering |
| 12 Mar 2025 | Pengumuman | Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities |
| 12 Mar 2025 | Pengumuman | Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering |
| 26 Feb 2025 | Pengumuman | Shuttle Pharma Provides Corporate Update and Reports 2024 Results |
| 21 Jan 2025 | Pengumuman | Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma |
| 07 Jan 2025 | Pengumuman | Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |